DOCSLIB.ORG

Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Comparative Effectiveness Review Number 41

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Comparative Effectiveness Review Number 41 Comparative Effectiveness Review Number 41 Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Comparative Effectiveness Review Number 41 Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10065-I Prepared by: Vanderbilt Evidence-based Practice Center Nashville, Tennessee Investigators: Jeff Andrews, M.D. Amanda Yunker, D.O., M.S.C.R. W. Stuart Reynolds, M.D. Frances E. Likis, Dr.P.H., N.P., C.N.M. Nila A. Sathe, M.A., M.L.I.S. Rebecca N. Jerome, M.L.I.S., M.P.H. AHRQ Publication No. 11(12)-EHC088-EF January 2012 This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10065-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. Persons using assistive technology may not be able to fully access information in this report. For assistance contact [email protected]. None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report. Suggested citation: Andrews J, Yunker A, Reynolds WS, Likis FE, Sathe NA, Jerome RN. Noncyclic Chronic Pelvic Pain Therapies for Women: Comparative Effectiveness. Comparative Effectiveness Review No. 41. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publicaton No. 11(12)-EHC088-EF. Rockville, MD: Agency for Healthcare Research and Quality. January 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm. ii Preface The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children’s Health Insurance Program (CHIP). AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting Comparative Effectiveness Reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered. Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm. AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family’s health can benefit from the evidence. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly. We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to [email protected]. Carolyn M. Clancy, M.D. Jean Slutsky, P.A., M.S.P.H. Director Director, Center for Outcomes and Evidence Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality Stephanie Chang, M.D., M.P.H. Shilpa Amin, M.D., MBsc., FAAFP Director Task Order Officer Evidence-based Practice Program Center for Outcomes and Evidence Center for Outcomes and Evidence Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality iii Acknowledgments We are indebted to a tireless group of colleagues who made this report possible. Each step of systematic reviews draws on the skills and attention of an entire team. We are grateful for the guidance and methodologic and editing expertise of Dr. Melissa McPheeters, who provided invaluable input for structuring the review and our approach to the literature. Dr. Mark Hartmann brought his attention to detail—and his commitment to perfection—to completion of the evidence tables. His ability to point out inconsistencies and enhance uniformity was key to ensuring smooth development of the evidence tables. Dr. Shanthi Krishnaswami provided an exacting and thorough approach to abstract and full- text review and developing evidence tables. Her input was key in ensuring that all relevant data were extracted and that tables were consistent. Ms. Kathy Lee provided valuable research assistance on this report, helping with logistics, checking and formatting tables, and locating citations. Ms. Rachel Bazan and Mr. Michael Tranchina were our energetic student workers. They spent hours helping to track and file documents and were always positive and always ready to ensure that the project investigators had what they needed to complete this review. Key Informants Esther Eisenberg, M.D., M.P.H. Project Scientist, Reproductive Medicine Network, National Institute of Child Health and Development Department of Obstetrics and Gynecology, Vanderbilt Medical Center Nashville, TN Fred M. Howard, M.D. Associate Chair, Academic Affairs Director, Division of Obstetric/Gynecologic Specialties Professor, Obstetrics and Gynecology University of Rochester Rochester, NY Georgine Lamvu, M.D., M.P.H., FACOG Medical Director Gynecologic Unit of Florida Hospital Orlando, FL Bruce Lessey, M.D., Ph.D. Vice Chair, Research Center for Women’s Medicine, Greenville Hospital System Greenville, SC iv Kerri Schuiling, Ph.D., CNM, WHNP-BC Associate Dean and Director, School of Nursing Northern Michigan University Marquette, MI Eric Wall, M.D., M.P.H. Senior Medical Director, Qualis Health Seattle, WA Rachel Williams, Ph.D. Glaxo Smith Kline Chapel Hill, NC Denniz Zolnoun, M.D., M.P.H. Department of Obstetrics and Gynecology University of North Carolina Chapel Hill, NC Technical Expert Panel Sawsan As-Sanie, M.D., M.P.H. Director, Chronic Pelvic Pain Program and Minimally Invasive Surgery Fellowship University of Michigan Ann Arbor, MI Esther Eisenberg, M.D., M.P.H. Project Scientist, Reproductive Medicine Network, National Institute of Child Health and Development Department of Obstetrics and Gynecology, Vanderbilt Medical Center Nashville, TN Bruce Lessey, M.D., Ph.D. Vice Chair, Research Center for Women’s Medicine, Greenville Hospital System Greenville, SC Steve Phurrough, M.D., M.P.A. Chief Operating Officer and Senior Clinical Director, Center for Medical Technology and Policy Baltimore, MD Frank Tu, M.D., M.P.H. Director, Division of Gynecological Pain and Minimally Invasive Surgery NorthShore University Health System Chicago, IL v Peer Reviewers Mary Lou Ballweg President and Executive Director Endometriosis Association Milwaukee, WI Georgine Lamvu, M.D., M.P.H., FACOG Medical Director Gynecologic Unit of Florida Hospital Orlando, FL Linda McGowan, Ph.D., M.Sc., B.Sc. School of Nursing, Midwifery and Social Work Faculty of Medical and Human Sciences University of Manchester Manchester,
Load more

Recommended publications
  • Clinical Practice Guideline for Limb Salvage Or Early Amputation
    Limb Salvage or Early Amputation Evidence-Based Clinical Practice Guideline Adopted by: The American Academy of Orthopaedic Surgeons Board of Directors December 6, 2019 Endorsed by: Please cite this guideline as: American Academy of Orthopaedic Surgeons. Limb Salvage or Early Amputation Evidence-Based Clinical Practice Guideline. https://www.aaos.org/globalassets/quality-and-practice-resources/dod/ lsa-cpg-final-draft-12-10-19.pdf Published December 6, 2019 View background material via the LSA CPG eAppendix Disclaimer This clinical practice guideline was developed by a physician volunteer clinical practice guideline development group based on a formal systematic review of the available scientific and clinical information and accepted approaches to treatment and/or diagnosis. This clinical practice guideline is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Clinical patients may not necessarily be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician’s independent medical judgment, given the individual patient’s specific clinical circumstances. Disclosure Requirement In accordance with AAOS policy, all individuals whose names appear as authors or contributors to this clinical practice guideline filed a disclosure statement as part of the submission process. All panel members provided full disclosure of potential conflicts of interest prior to voting on the recommendations contained within this clinical practice guideline. Funding Source This clinical practice guideline was funded exclusively through a research grant provided by the United States Department of Defense with no funding from outside commercial sources to support the development of this document.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Expression of Recombinant Human Androgen Receptor and Its Use for Screening Methods
    Institut für Physiologie FML Weihenstephan Technische Universität München Expression of recombinant human androgen receptor and its use for screening methods Ellinor Rose Sigrid Bauer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. B. Hock Prüfer der Dissertation: Univ.-Prof. Dr. H. H. D. Meyer Univ.-Prof. Dr. H. Sauerwein (Rheinische Friedrich-Wilhelms-Universität Bonn) Die Dissertation wurde am 31.10.2002 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 03.12.2002 angenommen. Introduction Content 1. INTRODUCTION ..................................................................................................................................... 5 1.1. ENDOCRINE DISRUPTERS 5 1.2. ANDROGENS AND ANTIANDROGENS 7 1.2.1. DEFINITIONS 7 1.2.2. MODE OF ACTION 8 1.3. STRUCTURES OF ENDOCRINE DISRUPTERS 10 1.4. STRATEGIES FOR MONITORING ANDROGEN ACTIVE SUBSTANCES 13 1.4.1. IN VIVO METHODS 13 1.4.2. IN VITRO METHODS 15 1.5. OBJEKTIVE OF THE STUDIES 18 2. MATERIALS AND METHODS ................................................................................................................. 19 2.1. PREPARATION OF RECEPTORS 19 2.2. ASSAY SYSTEMS 19 2.2.1. IN SOLUTION AR ASSAY 19 2.2.2. IMMUNO-IMMOBILISED RECEPTOR ASSAY (IRA) 20 2.2.3. PR AND SHBG ASSAYS 21 2.2.4. DATA EVALUATION 21 2.3. ANALYTES 22 3. RESULTS AND DISCUSSION ................................................................................................................. 23 3.1. DEVELOPMENT OF NEW ASSAY SYSTEMS 23 3.1.1. BAR ASSAY 23 3.1.2. CLONING OF THE HUMAN AR AND PRODUCTION OF FUNCTIONAL PROTEIN 24 3.1.3. DEVELOPMENT OF A SCREENING ASSAY ON MICROTITRE PLATES (IRA) 25 3.2.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Biological Research in the Evolution of Cancer Surgery: a Personal Perspective Bernard Fisher
    AACR Centennial Series Biological Research in the Evolution of Cancer Surgery: A Personal Perspective Bernard Fisher University of Pittsburgh, Pittsburgh, Pennsylvania Abstract Introduction During the 19th, and for most of the 20th century, malignant It is of historic interest that the American Association for Cancer tumors were removed by mutilating radical anatomic dissec- Research (AACR) was founded by four surgeons, five pathologists, tion. Advances such as anesthesia, asepsis, and blood one chemist, and a biochemist at the 25th meeting of the American transfusion made possible increasingly more radical oper- Surgical Association in Washington, DC, on May 7, 1907. The aim of ations. There was no scientific rationale for the operations the newly formed organization was to improve cancer research and being performed. Surgery in the 20th century was dominated treatment of cancer and to promote prevention. In recognition of by the principles of William S. Halsted, who contended that the 100th anniversary of the AACR, this article will examine the the bloodstream was of little significance as a route of tumor role biological research has played in the evolution of cancer cell dissemination; a tumor was autonomous of its host; and surgery. cancer was a local-regional disease that spread in an orderly Four principal aspects with regard to biological research will be fashion based on mechanical considerations. Halsted believed addressed:( a) whether research played a part in instigating surgical that both the extent and nuances of an operation influenced advances that occurred during the 19th and the first half of the patient outcome and that inadequate surgical skill was 20th centuries; (b) whether research formed the basis for the responsible for the failure to cure.
    [Show full text]
  • Female Pelvic Relaxation
    FEMALE PELVIC RELAXATION A Primer for Women with Pelvic Organ Prolapse Written by: ANDREW SIEGEL, M.D. An educational service provided by: BERGEN UROLOGICAL ASSOCIATES N.J. CENTER FOR PROSTATE CANCER & UROLOGY Andrew Siegel, M.D. • Martin Goldstein, M.D. Vincent Lanteri, M.D. • Michael Esposito, M.D. • Mutahar Ahmed, M.D. Gregory Lovallo, M.D. • Thomas Christiano, M.D. 255 Spring Valley Avenue Maywood, N.J. 07607 www.bergenurological.com www.roboticurology.com Table of Contents INTRODUCTION .................................................................1 WHY A UROLOGIST? ..........................................................2 PELVIC ANATOMY ..............................................................4 PROLAPSE URETHRA ....................................................................7 BLADDER .....................................................................7 RECTUM ......................................................................8 PERINEUM ..................................................................9 SMALL INTESTINE .....................................................9 VAGINAL VAULT .......................................................10 UTERUS .....................................................................11 EVALUATION OF PROLAPSE ............................................11 SURGICAL REPAIR OF PELVIC PROLAPSE .....................15 STRESS INCONTINENCE .........................................16 CYSTOCELE ..............................................................18 RECTOCELE/PERINEAL LAXITY .............................19
    [Show full text]
  • En Bloc Resection of Extra-Peritoneal Soft Tissue Neoplasms Incorporating a Type III Internal Hemipelvectomy: a Novel Approach Sanjay S Reddy1* and Norman D Bloom2
    Reddy and Bloom World Journal of Surgical Oncology 2012, 10:222 http://www.wjso.com/content/10/1/222 WORLD JOURNAL OF SURGICAL ONCOLOGY REVIEW Open Access En bloc resection of extra-peritoneal soft tissue neoplasms incorporating a type III internal hemipelvectomy: a novel approach Sanjay S Reddy1* and Norman D Bloom2 Abstract Background: A type III hemipelvectomy has been utilized for the resection of tumors arising from the superior or inferior pubic rami. Methods: In eight patients, we incorporated a type III internal hemipelvectomy to achieve an en bloc R0 resection for tumors extending through the obturator foramen or into the ischiorectal fossa. The pelvic ring was reconstructed utilizing marlex mesh. This allowed for pelvic stability and abdominal wall reconstruction with obliteration of the obturator space to prevent herniations. Results: All eight patients had an R0 resection with an overall survival of 88% and with average follow up of 9.5 years. Functional evaluation utilizing the Enneking classification system, which evaluates motion, pain, stability and strength of the affected extremity, revealed a 62% excellent result and a 37% good result. No significant complications were associated with the operative procedure. Marlex mesh reconstruction provided pelvic stability and eliminated all hernial defects. Conclusion: The superior and inferior pubic rami provide a barrier to a resection for tumors that arise in the extra-peritoneal pelvis extending through the obturator foramen or ischiorectal fossa. Incorporating a type III internal
    [Show full text]
  • Pessary Information
    est Ridge obstetrics & gynecology, LLP 3101 West Ridge Road, Rochester, NY 14626 1682 Empire Boulevard, Webster, NY 14580 www.wrog.org Tel. (585) 225‐1580 Fax (585) 225‐2040 Tel. (585) 671‐6790 Fax (585) 671‐1931 USE OF THE PESSARY The pessary is one of the oldest medical devices available. Pessaries remain a useful device for the nonsurgical treatment of a number of gynecologic conditions including pelvic prolapse and stress urinary incontinence. Pelvic Support Defects The pelvic organs including the bladder, uterus, and rectum are held in place by several layers of muscles and strong tissues. Weaknesses in this tissue can lead to pelvic support defects, or prolapse. Multiple vaginal deliveries can weaken the tissues of the pelvic floor. Weakness of the pelvic floor is also more likely in women who have had a hysterectomy or other pelvic surgery, or in women who have conditions that involve repetitive bearing down, such as chronic constipation, chronic coughing or repetitive heavy lifting. Although surgical repair of certain pelvic support defects offers a more permanent solution, some patients may elect to use a pessary as a very reasonable treatment option. Classification of Uterine Prolapse: Uterine prolapse is classified by degree. In first‐degree uterine prolapse, the cervix drops to just above the opening of the vagina. In third‐degree prolapse, or procidentia, the entire uterus is outside of the vaginal opening. Uterine prolapse can be associated with incontinence. Types of Vaginal Prolapse: . Cystocele ‐ refers to the bladder falling down . Rectocele ‐ refers to the rectum falling down . Enterocele ‐ refers to the small intestines falling down .
    [Show full text]
  • Obstetrics and Gyneclogy
    3/28/2016 Obstetrics and Gynecology Presented by: Peggy Stilley, CPC, CPC-I, CPMA, CPB, COBGC Objectives • Procedures • Pregnancy • Payments • Patient Relationships 1 3/28/2016 Female Genital Anatomy Terminology and Abbreviations • Endometriosis • Neoplasm • BUS • TAH/BSO • G3P2 2 3/28/2016 Procedures • Hysterectomy • Prolapse repairs • IUDs • Colposcopy Hysterectomy • Approach • Open • Vaginal • Total Laparoscopic • Laparoscopic assisted • Extent • Total • Subtotal • Supracervical • Diagnosis 3 3/28/2016 CPT Codes • Abdominal 58150 – • With or without removal tubes/ovaries 58240 • Some additional services • Vaginal 58260-58270 • Size of uterus < 250 grams, > 250 grams 58275-58294 • Additional services CPT Codes • LAVH 58541-58544 • Detach uterus , cervix, and structures through the scope 58548-58554 • Uterus removed thru the vagina • TLH • Detach structures laparoscopically entire 58570- 58573 uterus, cervix, bodies • Removed thru the vagina or abdomen • LSH • Detaching structures through the scope, 58541 – 58544 leaving the cervix • Morcellating – removing abdominally 4 3/28/2016 Hysterectomy Additional procedures performed • Tubes & Ovaries removed • Enterocele repair • Repairs for incontinence • Marshall-Marchetti-Krantz • Colporrhaphy • Colpo-urethropexy • Urethral Sling • TVT, TOT 5 3/28/2016 Procedures • 57288 Sling • 57240 Anterior Repair • 57250 Posterior Repair • +57267 Add on code for mesh/graft • 57260 Combo of A&P • 57425 Laparoscopic Colpopexy • 57280 Colpopexy, Abdominal approach • 57282 Colpopexy, vaginal approach Example 1 PREOPERATIVE DIAGNOSES: 1. Menorrhagia unresponsive to medical treatment with resulting chronic blood loss anemia POSTOPERATIVE DIAGNOSES: 1. Menorrhagia 2. Blood loss anemia TITLE OF SURGERY: Total abdominal hysterectomy ANESTHESIA: GENERAL ENDOTRACHEAL ANESTHESIA. INDICATIONS: The patient is a lovely 52-year-old female who presented with menorrhagia that is non- responsive to medical treatment.
    [Show full text]
  • The Metabolism of Anabolic Agents in the Racing Greyhound
    The Metabolism of Anabolic Agents In the Racing Greyhound A thesis submitted in partial fulfilment of the requirements for the Degree of Doctor of Philosophy by Mr. Keith Robert Williams, B.Sc. July 1999 Department of Forensic Medicine & Science University of Glasgow Copyright © 1999 by Keith R. Williams. All rights reserved. No part o f this thesis may be reproduced in any forms or by any means without the written permission o f the author. I ProQuest Number: 13833925 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13833925 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 GLASGOW UNIVERSITY LIBRARY 111-X (coK To my parents for all their help, support and encouragement i Table of Contents i List of Figures V List of Tables VIII Summary IX Chapter 1: Drugs in Sport ...............................................................................................................................1 Introduction .................................................................................................................................................
    [Show full text]
  • Electromyography and Nerve Conduction Studies in Patients With
    ogy & N ol eu ur e ro N p h f y o s l Ziegler MS, J Neurol Neurophysiol 2014, 5:3 i o a l n o r g u y o DOI: 10.4172/2155-9562.1000203 J Journal of Neurology & Neurophysiology ISSN: 2155-9562 Research Article Open Access Electromyography and Nerve Conduction Studies in Patients with Lumbar Spinal Stenosis: Is Neurophysiological Examination an Important Tool? Marcus Sofia Ziegler1, Renata Siciliani Scalco2, Erasmo de Abreu Zardo1, Jefferson Becker2 and Irenio Gomes2* 1Department of Orthopaedics & Spine Surgery, Hospital São Lucas Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil 2Department of Neurology, Hospital São Lucas Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil *Corresponding author: Irenio Gomes, Hospital Sao Lucas, and Avenida Ipiranga 6690 - 3 ºandar - IGG Porto Alegre - RS – Brasil, CEP 90610-000, Tel: +55 (51) 3336.8153 / 3320.3000; E-mail: [email protected] Received Date: Jan 21, 2014 Accepted Date: Apr 25, 2014 Published Date: Apr 30, 2014 Copyright: © 2014 Ziegler MS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: There is no single test that defines properly lumbar spinal stenosis (LSS) diagnosis, and diagnosis of the syndrome continues to rely on clinical judgment. LSS symptoms may be broad and may be seen in multiple disorders in elderly. Hypothesis: To identify the role of electromyography and nerve-conduction studies on LSS diagnosis.
    [Show full text]